Graybug Vision Jumps 25%

Shares of Graybug Vision Inc. (GRAY) are climbing over 25% on Monday's trading despite no stock-related news to drive the shares.

GRAY is currently trading at $6.55, up $1.35 or 25.96%, on the Nasdaq. On a volume of 14.2 million shares, far above the average volume of 1.9 million.The stock has traded between $3.43 and $37.88 in the 52 week period.

Graybug Vision, a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT